The uncommon fungal pathogen Trichoderma shows increasing medical importance particularly in immunocompromised patients. Despite systemic antifungal therapy, prognosis of Trichoderma infection is poor regardless of the type of infection and the therapy used. The aim of the present study was to evaluate the in vitro activity and synergism of double antifungal combinations including amphotericin B, voriconazole, fluconazole, chlorhexidine digluconate and Akacid plus Ò against 15 isolates of Trichoderma longibrachiatum and 1 isolate of Trichoderma harzianum.
Introduction
Trichoderma species are saprophytic filamentous fungi with worldwide distribution in the soil, plant material, decaying vegetation and wood. Although Trichoderma is commonly considered as a contaminant, several case studies on infections in humans with this uncommon mould have revealed that this fungal pathogen shows increasing medical importance particularly in immunocompromised patients, such as neutropenic cases and transplant recipients as well as patients with chronic renal failure. 1 The genus Trichoderma has five medically relevant species Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma pseudokoningii and Trichoderma viride. T. longibrachiatum is the main human pathogen species within the genus.
The treatment of Trichoderma infections in humans requires systemic antifungal therapy, removal of the foreign bodies, surgical intervention and therapy of the underlying disease.
2-5 Despite antimicrobial therapy with amphotericin B alone or in combination, prognosis of Trichoderma infection is poor regardless of the type of infection and the therapy used. 1 Previous reports on antifungal susceptibility testing against T. longibrachiatum have documented elevated MICs of conventional antimycotics such as amphotericin B, fluconazole, itraconazole and flucytosine. 
Materials and Methods

Fungi
Twelve clinical isolates of T. longibrachiatum including ATCC 201044 and ATCC 208859, one clinical isolate of T. harzianum (CBS 102174) and three environmental isolates of T. longibrachiatum CECT 2937, CECT 20105 and CECT 2606 were tested. Clinical or environmental origin of these isolates is shown in Table 1 . The identity of all strains of T. longibrachiatum and T. harzianum was confirmed by internal transcribed spacer sequence (GenBank accession numbers AY328034,-35,-37,-38,-39,-40,-41,-42; AY585879,-80; AY920396,-97,-98; Z82912; X93929) analysis. T. longibrachiatum IP 2110.92 and CNM-CM-382, which were originally identified as T. pseudokoningii 4 and T. koningii, 7 were reidentified as T. longibrachiatum based on ITS sequence analysis and PCR-fingerprinting.
Antifungal susceptibility testing
Amphotericin B (Bristol-Myers Squibb, Epernon, France), fluconazole (Pfizer, Amboise, France) and voriconazole (Pfizer) were purchased as standard powders. Stock solutions of amphotericin B and voriconazole were prepared in 100% dimethyl sulphoxide, and fluconazole powder was dissolved in distilled water. Akacid plus Ò , a 3:1 mixture of poly-(hexamethylen-guanidinium-chloride) and poly-[2-(2-ethoxy)-ethoxyethyl)-guanidinium-chloride], (PoC, Vienna, Austria) and chlorhexidine digluconate (Sigma, St Louis, MO, USA) were acquired as 25% and 20% aqueous solutions.
The individual MICs were determined initially by using broth microdilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) for moulds with standard RPMI 1640 broth buffered to pH 7 with 0.165 M MOPS and supplemented to 2% glucose. 8 Inoculum conidial stock suspensions were prepared in sterile saline containing 1% polysorbate 80 from fresh, mature (5-to 7-day-old) cultures on potato dextrose agar at 25 C. The inoculum size was adjusted to an optical density that ranged from 0.09 to 0.13 (0.5-2.5 · 10 6 non-germinated conidia/ mL suspension). The suspensions were then diluted 1:50 to obtain a final working inoculum of 1-5 · 10 4 cfu/mL. Fungal inocula (100 mL) were added to each well of the microdilution tray, and each well contained 100 mL of drug solution (2· final concentration). The plates were incubated at 35 C and were read visually after 48 h of incubation. MICs were defined as the lowest concentration of the antifungal agent that completely inhibited the fungal growth. Drug-free and fungus-free controls were included; quality control was ensured by testing Aspergillus niger ATCC 16404, A. niger ATCC 10578, A. fumigatus ATCC 14110, Candida krusei ATCC 6258 and Candida tropicalis ATCC 750, respectively.
Chequerboard tests were employed to determine the in vitro efficacy of each double combination for each test isolate. Quantitative analysis of antifungal combinations was performed as described previously. 9 The fractional inhibitory concentration (FIC) of each drug for an individual isolate was calculated as the ratio of the MIC of the drug in combination to the MIC of the drug alone. The FIC index (FICI) value for an individual isolate was calculated by adding the 
Results
Antimicrobial activity
Results of the individual MICs of conventional and cationic antimicrobials are illustrated in Table 1 . Fluconazole reached the highest MIC values ranging from 64 to 256 mg/L against all tested isolates of T. longibrachiatum, even a higher MIC of 1024 mg/L was found against T. harzianum CBS 102174. Apart from only one environmental strain, all clinical Trichoderma isolates showed reduced susceptibility to amphotericin B (MICs = 2 mg/L). Lower MICs of 0.5-1 mg/L were detected for voriconazole. The novel biocide Akacid plus Ò reached MIC values ranging from 0.06 to 0.5 mg/L, whereas 4-to 32-fold higher MICs were determined for chlorhexidine digluconate.
Overall synergy results of Trichoderma isolates are summarized in Table 2 . No antagonism was observed for any of the antifungal combinations tested. In vitro interaction of amphotericin and azoles was indifferent for all Trichoderma strains; FICI values ranging from 2 to 4 were determined. Voriconazole and fluconazole in combination also appeared to be indifferent for most strains (FICI 50 = 2). The synergy tests of one conventional antifungal and one cationic antimicrobial resulted in a synergistic or indifferent effect. Interactions of azoles and chlorhexidine were synergistic for most strains (FICI 50 = 0.28 or 0.31) and synergistic to indifferent for all strains (FICI 90 = 0.54 or 0.88). In general, azoles MICs in combination decreased one to nine 2-fold dilutions, whereas chlorhexidine in combination decreased only slightly (one to three 2-fold dilutions). Interactions of azoles with Akacid plus Ò were synergistic in 25% and 37.5% of the tested isolates. The combination of both cationic antimicrobials showed synergism for all Trichoderma isolates (FICI 90 = 0.39). Akacid plus Ò MICs in combination decreased three to seven 2-fold dilutions, while chlorhexidine MICs decreased only two to five 2-fold dilutions.
Discussion
The present study demonstrated reduced activity of fluconazole and amphotericin B and higher in vitro activity of voriconazole against clinical and environmental Trichoderma isolates. Tested MIC values of these conventional antifungals were comparable to those previously reported in the literature for this species. 2, 5 According to the CLSI document, no breakpoints exist for the definition of resistance in filamentous fungi. 8 The difficulty in treating invasive mould infections could be explained because of poor penetration of antifungal agents into infected tissue. Voriconazole which is registered for the treatment of systemic Aspergillus, Candida, Fusarium spp. and Scedosporium infections penetrates well in the central nervous system. Due to lower MIC values, fewer side effects and higher penetration than amphotericin B, voriconazole might be an important drug in the treatment of invasive Trichoderma infections.
Previous in vitro studies on combination of antifungal drugs against the most common mould species Aspergillus spp. have resulted in controversial findings. 9 Our synergy tests revealed indifferent interaction between amphotericin B and azoles against Trichoderma spp. The combination of voriconazole or fluconazole with Akacid plus Ò or chlorhexidine showed different degrees of synergism, whereas the interaction of both cationic antimicrobials was synergistic for each Trichoderma isolate.
Although some cases of superficial or localized Trichoderma infections such as sinusitis, 3 stomatitis, infection of the skin 2 and otitis externa 1 are reported in literature, mostly the diagnosis of Trichoderma spp. is not made until dissemination of the fungi where fine septate hyphae are found in lungs, brain, heart, liver, stomach and pretracheal abscesses. An earlier diagnosis of Trichoderma spp. could enable the clinical application of cationic antimicrobials to support the treatment of localized Trichoderma infections in the future. 
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